<div id="readability-page-1"><p>Myriad Genetics, Inc. (NASDAQ:MYGN - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the fourteen analysts that are presently  covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued  a buy rating on  the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.50.</p><div><p><span></span><span>Get <strong>Myriad Genetics</strong> alerts:</span></p></div><ul><li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li></ul><p>MYGN has been the subject of a number of research reports. Piper Sandler lowered their price target on Myriad Genetics from $9.00 to $8.50 and set an &#34;overweight&#34; rating for the company in a report on Tuesday, November 11th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Myriad Genetics in a report on Monday. Cowen  reiterated a &#34;hold&#34; rating on shares of Myriad Genetics in a report on Tuesday, November 4th. UBS Group upped their price target on shares of Myriad Genetics from $6.00 to $8.00 and gave the stock a &#34;neutral&#34; rating in a research report on Tuesday, November 4th. Finally, Wells Fargo &amp; Company lifted their price objective on shares of Myriad Genetics from $6.00 to $6.50 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 5th.</p><p><b>Get Our Latest Report on MYGN</b></p><h2>Institutional Inflows and Outflows</h2><ul><li>Exact Sciences Serves Investors Exactly What They Wished For </li></ul><p>A number of institutional investors and hedge funds have recently modified their holdings of MYGN. Vanguard Group Inc. boosted its stake in  Myriad Genetics by 0.7% in the first quarter. Vanguard Group Inc. now owns 10,667,755 shares of the company's stock valued at $94,623,000 after acquiring an additional 76,712 shares in the last quarter.  Glenview Capital Management LLC boosted its position in shares of  Myriad Genetics by 17.6% in the 2nd quarter. Glenview Capital Management LLC now owns 4,587,407 shares of the company's stock worth $24,359,000 after purchasing an additional 687,857 shares in the last quarter.  Jacobs Levy Equity Management Inc. increased its position in  Myriad Genetics by 157.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company's stock valued at $17,662,000 after buying an additional 1,492,405 shares in the last quarter.  Qube Research &amp; Technologies Ltd raised its stake in  Myriad Genetics by 44.7% in the second quarter. Qube Research &amp; Technologies Ltd now owns 2,051,588 shares of the company's stock valued at $10,894,000 after buying an additional 633,439 shares during the last quarter.  Finally, Connor Clark &amp; Lunn Investment Management Ltd. boosted its holdings in  Myriad Genetics by 50.5% in the second quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 1,387,832 shares of the company's stock worth $7,369,000 after acquiring an additional 465,921 shares in the last quarter. Hedge funds and other institutional investors own  99.02% of the company's stock. </p><h2>Myriad Genetics Stock Down 1.6%</h2><p>Shares of NASDAQ:MYGN opened at $6.88 on Wednesday. The firm has a market capitalization of $641.28 million, a PE ratio of -1.59 and a beta of 1.81. The business has a 50 day simple moving average of $7.35 and a two-hundred day simple moving average of $6.37. Myriad Genetics has a 1 year low of $3.76 and a 1 year high of $15.47. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.33 and a quick ratio of 2.12. </p><p>Myriad Genetics (NASDAQ:MYGN - Get Free Report) last released its earnings results on Tuesday, January 16th. The company reported ($0.19) earnings per share for the quarter. Myriad Genetics had a negative return on equity of 7.11% and a negative net margin of 48.53%.The business had revenue of $156.40 million during the quarter. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS.  On average, equities analysts predict that  Myriad Genetics will post -0.3 EPS for the current year. </p><h2>About Myriad Genetics</h2> (Get Free Report)<p>Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Myriad Genetics</li><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li><li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li><li>A Deeper Look at Bid-Ask Spreads</li><li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li><li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion </li><li>RTX Surges to Record Highs as Defense Orders Explode</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVlHTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Myriad Genetics Right Now?</h2><p>Before you consider Myriad Genetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myriad Genetics wasn't on the list.</p><p>While Myriad Genetics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MYGN

<p>Myriad Genetics, Inc. (NASDAQ:MYGN) has received a consensus 'Hold' rating from 14 analysts, with varied ratings from sell to buy. The average price target is $10.50. Institutional investors have adjusted their holdings, with significant changes in shares owned. The stock opened at $6.88, with a market cap of $641.28 million. The company reported a negative EPS of ($0.19) and set FY23 guidance at ($0.33)-($0.28) EPS. Myriad Genetics offers genetic tests for oncology and other medical fields.</p>

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Brokerages